Holen Sie sich die Stockscreener-App
5.91
1.50%
-0.09
Handel nachbörslich:
5.89
-0.02
-0.34%
Schlusskurs vom Vortag:
$6.00
Offen:
$6.01
24-Stunden-Volumen:
60,725
Relative Volume:
1.29
Marktkapitalisierung:
$66.08M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-43.07M
KGV:
-0.9157
EPS:
-6.4543
Netto-Cashflow:
$-47.84M
1W Leistung:
+1.20%
1M Leistung:
-14.47%
6M Leistung:
-35.34%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.88
$6.505
1-Wochen-Bereich:
$5.8221
$6.505
52-Wochen-Spanne:
$5.70
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Firmenname
Imagenebio Inc
Sektor
Branche
Telefon
857-343-8292
Adresse
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
5.91 | 67.09M | 3.50M | -43.07M | -47.84M | -6.4543 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Fortgesetzt | Wedbush | Underperform |
| 2025-10-24 | Eingeleitet | Leerink Partners | Outperform |
Imagenebio Inc Aktie (IMA) Neueste Nachrichten
ImageneBio, Inc. 2025 10-K: IMG-007 Clinical Development, Strategy, and Market Opportunities in Immunological Diseases - Minichart
Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance - TipRanks
ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ImageneBio 10-K: License revenue $0.8M; Net loss $45.3M - TradingView
ImageneBio (NASDAQ: IMA) bets on OX40 antibody IMG-007 after Ikena merger - Stock Titan
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - The Manila Times
Blue Owl Capital Holdings LP Purchases New Stake in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
IMA,CVRX Revenue Breakdown - Finviz
ImageneBio to Participate in Leerink Global Healthcare Conference - Eagle-Tribune
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World
ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy? - Defense World
ImageneBio announces immediate resignation of board director - TipRanks
ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan
ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026 - marketscreener.com
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com Nigeria
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com South Africa
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - marketscreener.com
New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan
ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS
ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance
Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks
Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat
ImageneBio chief medical officer resigns, transition planned - MSN
ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks
ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com
ImageneBio assumed at Underperform from Neutral at Wedbush - MSN
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World
ImageneBio Extends Agreement with Miragene Inc. - MSN
ImageneBio (IMA) price target decreased by 94.20% to 16.32 - MSN
ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga
ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat
ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World
IMA interactive stock chart | ImageneBio, Inc. stock - Yahoo Finance Australia
Price performance - Yahoo Finance Australia
ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World
Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks
Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa
ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus
Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India
Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - marketscreener.com
ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - MSN
Finanzdaten der Imagenebio Inc-Aktie (IMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):